Uricosuric, antioxidant, and anti-inflammatory properties of Pandanus amaryllifolius Roxb. extract against potassium oxonate-induced hyperuricemia in rats Authors: Panan Suntornsaratoon, Wajathip Bulanawichit, Sinee Siricoon, Vitoon Saengsirisuwan, Nattapon Panupinthu, Nateetip Krishnamra, Narattaphol Charoenphandhu Published: 2025 ABSTRACT High serum uric acid (HUA) is linked to gout, fatty liver, and insulin resistance. Anti-hyperuricemic drugs were designed to lower uric acid production and/or inhibit urate reabsorption by renal and extra-renal tissues. While Pandanus amaryllifolius Roxb. ex Lindl. extract (PA) was reported to reduce uric acid production, the full effects of PA on urate metabolism were unclear. This study investigated PA impact on uric acid reabsorption and excretion in Wistar rats with potassium oxonate-induced HUA. Hyperuricemic rats showed elevated uric acid, reduced urinary excretion, decreased antioxidants, β-cell dysfunction, hyperglycemia, kidney damage, and hepatic fat. PA supplementation (0.5, 1, and 2 g/kg) for 14 days lowered serum xanthine oxidase activity and uric acid levels, comparable to benzbromarone and less potently than allopurinol. This reduction was achieved by suppressing urate reabsorption and enhancing renal and intestinal urate excretion. Furthermore, PA alleviated β-cell dysfunction and hyperglycemia by improving insulin secretion and signaling (IRS1 and Akt activation). It also reduced hepatic lipid synthesis, stimulated lipolysis, and decreased hepatic fat accumulation and pro-inflammatory cytokines. These findings demonstrate PA xanthine oxidase inhibitory, uricosuric, antioxidant, and anti-inflammatory properties, highlighting its potential as a therapeutic agent for hyperuricemia and related hyperglycemia.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-27933-7. Introduction Gout is an inflammatory disease manifested by deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons and soft tissues. Renal handling of urate has a pivotal role in uric acid homeostasis involving a complex interplay of reabsorption and secretion primarily in the proximal tubule1. Disruption of renal handling of urate frequently leads to elevated blood uric acid level (hyperuricemia) and gouty arthritis. Urate is normally reabsorbed by tubular cells via URAT1 and GLUT9 in apical and basolateral membrane, respectively, while it is secreted by ABCG2 (ATP-binding cassette subfamily G member 2) or NPT1/4 in apical membrane and OAT1/3, the basolateral urate transporter1. Hyperuricemia is generally caused by increased uric acid production or impaired uric acid excretion or a combination of these two mechanisms2,3. High serum level of uric acid has been known for over a decade to result in deposition of monosodium urate (MSU) in joints and other tissues4, which consequently activates inflammatory cytokine production and accumulation of macrophages and neutrophils thus leading to gouty arthritis5. Besides gout, hyperuricemia is also a prominent risk factor for hypertension and diabetes. Serum urate concentration was reported to positively correlate with the degree of central adiposity and insulin resistance6,7, the underlying mechanism of this urate-induced changes has only been partially elucidated. Oxidative stress has an important role in the pathogenesis of gout and is responsible for a series of inflammatory events4,7. Hyperuricemia-induced oxidative stress was known to activate NLRP3 inflammasome, a cytoplasmic polyprotein complex, leading to renal tubule inflammation and injury8,9. In addition, soluble uric acid directly increased NLRP3 expression, caspase-1 activation, and IL-1β in the renal proximal tubule epithelial cells in a toll-like receptor 4 dependent manner10 and induced renal inflammation via NF-𝛋B signaling pathway in the renal tubular epithelium11. High level of soluble uric acid also caused mitochondria damage in renal tubular epithelial cells, resulting in excessive ROS release and NLRP3 inflammasome activation, which in turn resulted in pyroptosis8,12. Furthermore, in vitro and in vivo studies showed that hyperuricemia was associated with non-alcoholic fatty liver disease (NAFLD)13,14, whereby, high uric acid triggered the NLRP3 inflammasome formation and subsequent secretion of IL-18 and IL-1β. NLRP3 activation was apparently a key contributor to amplified hepatic inflammation, immune cell activation and hepatocyte damage. Thus, NLRP3 inflammasome could instigate a series of serious conditions, ranging from benign NAFLD to fibrosis15. Over production of uric acid could be due to an overactivation of xanthine oxidase, an enzyme that converts hypoxanthine into xanthine, and then into uric acid for excretion in the urine16. Xanthine oxidase inhibitors, such as allopurinol and febuxostat, are commercial drugs that are widely used to inhibit the activity of xanthine oxidase which effectively reduces plasma urate concentration to a level low enough to dissolve sodium urate crystals17. However, a number of adverse effects have been reported, including hepatotoxicity, nephrotoxicity, bone marrow suppression and hypersensitive bodily reactions17–19, thus limiting the use of these drugs. Therefore, alternative agents preferably with less side effects for hyperuricemia management are needed. In vivo and in vitro studies have demonstrated that Pandanus sp. possess anti-hyperuricemic, anti-hyperglycemic, anti-inflammatory and antioxidant properties20–25. Shukor and co-workers (2018)21 demonstrated that Pandanus amaryllifolius leaf extract exhibited xanthine oxidase inhibitory activities in Sprague Dawley male rats and in vitro assay. Molecular docking technique revealed that the ligand (E, E)-Pandanamine, a constituent of Pandanus leaves, as a promising, non-carcinogenic inhibitor of xanthine oxidase, suggesting a favorable safety profile for human application26. Despite these findings, the precise mechanism underlying the anti-hyperuricemic effect of Pandanus remains to be fully elucidated. Specifically, it is currently unclear whether Pandanus amaryllifolius primarily acts through xanthine oxidase inhibition, or if it also exhibits a uricosuric action similar to benzbromarone, which reduces urate reabsorption by inhibiting apical urate exchanger (URAT1) in the renal proximal tubule. Additionally, a study of Pandanus sp. in lipopolysaccharide-stimulated murine macrophage RAW 264.7 cells showed its suppressive effect on the production of pro-inflammatory cytokines, interleukin (IL)−1β, IL-6 and tumor necrosis factor-𝛂20. Thus, this study was designed to further investigate the anti-hyperuricemic, uricosuric, and anti-inflammatory properties of Pandanus amaryllifolius extract in a potassium oxonate-induced hyperuricemic rat model. It was hypothesized that Pandanus amaryllifolius could ameliorate hyperuricemia, as well as mitigate the associated hepatic fat accumulation and insulin resistance. Materials and methods Animals Seven- to eight-week old male WMN/Nrs rats (designation refers to an inbred Wistar rat strain specifically derived from the National Institute of Radiological Science (NRS) in Chiba, Japan. The lineage indicators “M” and “N” denote specific selection or maintenance characteristics within this inbred Wistar stock), weighing 200 ± 20 g, obtained from the National Laboratory Animal Center, Salaya, Nakhon Pathom, Thailand, were acclimatized in a controlled environment of 25 ± 2 °C, on a 12:12-h light-dark cycle with an average illumination of 200 lx for 7 days before experiment. Animals were fed with rodent chow containing 1.0% w/w calcium, 0.70% w/w phosphorus and 4,000 IU/kg 25(OH)D3 (CP, Bangkok, Thailand) ad libitum with free access to reverse osmosis (RO) water, which removes up to 99% of contaminants, including metal ions, organic compounds, and heavy metals. The present research was approved by the Animal Care and Use Committee, Faculty of Science, Mahidol University, Bangkok, Thailand. Animal Protocol number MUSC65-035-628. Central Animal Facility, Faculty of Science, Mahidol University has been international accredited by AAALAC. All experiments and methods used in the present study were performed in accordance with relevant regulations, and the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guideline. All rats were anesthetized by intraperitoneal injection to attain general anesthesia using a combination of 5 mg/kg xylazine (Thai Meiji Pharmaceutical Co., Ltd., Bangkok, Thailand) and 40 mg/kg tiletamine/zolazepam (zoletil; Virbac Laboratories, Carros, France). All anesthetized animals were carefully assessed for the absence of pain response and confirmation of unconsciousness prior to sample collection. After blood and tissue collection, euthanasia was performed using a second intraperitoneal injection of 15 mg/kg xylazine and 120 mg/kg zoletil, followed by cardiac removal. These protocols minimized animal distress and ensured humane euthanasia. Experimental designs To investigate the hypouricemic and uricosuric properties of PA extract, rats were acclimatized for 1 week, and later randomly divided into control group (n = 5) and potassium oxonate-induced hyperuricemic group (n = 30)27. Hyperuricemic rats (HUA) were randomly subdivided into 6 groups (n = 5 each), i.e., vehicle-treated (denoted as P0, 3% Tween-20), PA oral administration in the dose of 0.5, 1, and 2 g/kg (denoted as P0.5, P1 and P2, respectively), allopurinol (Allo; 5 mg/kg), and benzbromarone (Benz; 10 mg/kg). All 6 groups were fasted for 2 h prior to receiving 250 mg/kg potassium oxonate intraperitoneally on experimental day 1 st, 7th and 14th. They were individually housed in metabolic cage for 24 h to collect urine samples. Blood was collected from the tail vein 2 h post-injection to determine serum levels of uric acid. On the last experimental day, rats were fasted for 12 h before being euthanized 2 h after last dose of PA or drug administration. Ileum and kidney were collected for determination of mRNA/protein expression of urate transporters. Liver and kidney were collected for determination of pro-inflammatory cytokine expression and histopathology. EDTA-blood samples were used to detect HbA1C. Serum samples were kept at − 80 °C until analysis. Source of Pandanus amaryllifolius Pandanus amaryllifolius (PA) was harvested from a well-controlled farm with explicit permission from the landowner (Supplementary material 1) in Lat Takhian, Kabin Buri, Prachinburi Province (latitude: 14° 02’ 31.20” N; longitude: 101° 22’ 12.59” E), Thailand. General information about this species including the taxonomy is available at https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:670690-1 and http://www.efloras.org/florataxon.aspx?flora_id=2&taxon_id=242335482. Pandanus amaryllifolius Roxb. ex Lindl. was identified by professional botanists Paweena Traiperm, Ph.D., Sunisa Sangvirotjanapat, Ph.D., and Piriya Hassa, based on detailed plant characteristics. Voucher specimens of Pandanus amaryllifolius have been deposited at herbarium of Mahidol University (Institute Establishment for Sireeruckhachati Nature Learning Park Project) with deposition number PBM 006531–006532. A certificate of specimen deposition and authentication was included as Supplementary material 2. Pandanus amaryllifolius extraction Pandanus amaryllifolius leaves were washed with purified water and dried overnight in hot air oven at 50 °C. Dry leaves (100 g) were stirred well with 95% v/v ethanol 1.2 L (in ratio of 1:12) for 10 min, followed by 24-hour incubation at 25 °C, then the mixture was filtered by Whatman No.1 filter paper. Leaves were re-extracted 2 more times. Three filtrates were pooled and the solvent was evaporated for 96 h at 46 °C. PA extract was kept frozen at − 20 °C. PA extract solution, was always freshly prepared by diluting in 3% Tween 20 before being administered to experimental animals. Determination of total phenolic content and total flavonoid content Total phenolic content of PA extract was determined in three independent samples by Folin-Ciocalteu method. A standard curve was prepared in duplicate by using seven different concentrations of gallic acid, namely, 6.25, 12.5, 25, 50, 100, 200 and 400 mg/mL. Twenty-five microliters of gallic acid and samples were diluted with 75 µl of deionized water. Each sample was mixed well with 20 µl of Folin-Ciocalteu solution (Merch, Germany) and allowed to stand at room temperature for 6 min. Thereafter, 100 µl of 7% of sodium carbonate solution was added to the reaction mixtures and further allowed to stand in the dark environment for 90 min. The absorbance was measured at 765 nm using a spectrophotometer (Infinite M200 Pro, Tecan). Total flavonoid content was determined by colorimetric assay kit (E-BC-K284-S, Elabscience) according to the manufacturer’s instructions. Briefly, 0.54 mL of PA solution or standard flavonoid solution was added to a 2-mL microcentrifuge tube. Thirty microliters of saline solution and aluminium reagent were added, mixed thoroughly with the samples, and allowed to stand for 5 min at room temperature. Then, 0.4 mL of alkali reagent was added to the mixture. After 15 min, the absorbance was measured at 510 nm. Total flavonoid content was expressed as mg/g PA extract. Determination the activity of Xanthine oxidase, lipid peroxidation (malondialdehyde; MDA), antioxidant and level of insulin concentration Serum xanthine oxidase, MDA and antioxidants (SOD and GPX) were determine by commercial colorimetric assay kits (Cat No. ab102522 for xanthine oxidase, ab118970 for MDA, ab65354 for SOD and ab102530 for GPX, Abcam). Serum insulin concentration was determined by commercial ELISA (Cat No. EZRMI-13 K, Merck). Determination of intrahepatic triglyceride, Xanthine oxidase activity, and lipid peroxidation Intrahepatic triglyceride, xanthine oxidase and MDA were determined by commercial colorimetric assay kits (Cat No. ab65336, ab102522 and ab118970, respectively, Abcam) according to the manufacturer’s protocol. Approximately 100 mg of liver was homogenized in provided lysis buffer, centrifuged, and the supernatant was used to determine triglyceride content. Hepatic triglyceride content was expressed as nmol/mg tissue. As for MDA determination, liver homogenate was centrifuged at 3,000 × g at 4 °C, and the supernatant was determined for MDA and expressed as nmol/mg liver tissue. MDA, a metabolic product of lipid peroxidation, was used as a biomarker of oxidative stress28. Determination of serum lipid profile Whole blood was allowed to clot at room temperature for 30 min and subsequently centrifuged at 1500 × g for 10 min at 4 °C. (model D-37520; Kendro Laboratory Products, Hanau, Germany). Clotted blood samples were analyzed for full lipid profile at Ramathibodi Hospital laboratory (Bangkok, Thailand). Serum triglyceride levels were determined using a standard enzymatic colorimetric method (involving lipase and subsequent glycerol kinase/glycerol-3-phosphate oxidase). Total cholesterol was measured via the cholesterol oxidase enzyme reaction. HDL and LDL cholesterol were determined utilizing the widely accepted accelerator selective detergent method. Determination of uric acid level Urine was collected from 24-h housing in metabolic cage (Tecniplast; model 3701M081). Urine samples were centrifuged to remove any suspended particulate matter before testing. Levels of serum and urinary uric acid were determined by uric acid assay kit (ab65344, Abcam) according to manufactory’s protocol. Determination mRNA expression by RT-PCR Total RNA of renal cortex and liver was extracted using TRIzol reagent (Invitrogen, Carlsbad, United States) and the RNA concentration was quantitated by NanoDrop-2000c spectrophotometer (Thermo Specific, Waltham, MA, USA). Then, RNA was reverse-transcribed into cDNA by iScript cDNA Synthesis Kit (Bio-Rad Laboratories, CA, United State). Quantitative real-time PCR was performed by QuantStudio 3 Real-time PCR system (Applied Biosystems, MA, United State). Changes in mRNA expression were normalized by β-actin (ACTB) and presented as relative fold changes to control. The sequences of specific primers for uric acid transporters (i.e., URAT1, ABCG2, OAT3 and GLUT9), fatty acid synthesis markers (i.e., fatty acid synthase and SREBP-1c) lipolysis markers (i.e., PPARα and PGC-1α) and pro-inflammatory cytokines (i.e., IL1β and IL6) were shown in Supplemental Table 1. Determination of urate transporter protein expression by immunoperoxidase staining Ileum and renal cortex were washed with chilled 0.1 M phosphate-buffered saline (PBS) and fixed overnight in 4% paraformaldehyde. Tissues were embedded in paraffin wax and cut longitudinally into 4-µm sections. Tissue sections were deparaffinized, rehydrated and subjected to antigen retrieval as described in Supplemental Table 2. Then, they were incubated in 3% H2O2 in methanol for 30 min to quench endogenous peroxide activity. Non-specific bindings were blocked for 2 h by 5% normal goat serum and 0.1% Tween-20 in PBS. Thereafter, sections were further incubated at 4 °C overnight in moist chamber with primary antibodies. Thereafter, they were incubated for 1 h at room temperature with anti-rabbit conjugated with biotin (Cat No. 31820, Invitrogen) or anti-mouse conjugated with biotin (Cat No. 7688, Abcam) before being washed, and incubated for 1 more hour with Streptavidin HRP conjugate (Cat No. 434323, Invitrogen). The color was developed with DAB substrate chromogen system (Cat No. K3468, Dako). Determination of protein expression by Western blot Liver, kidney and ileum samples were homogenized in radioimmunoprecipitation assay (RIPA) buffer, then centrifuged for 10 min at 12,000 rpm. The supernatant was used for determination of protein concentrations by bicinchoninic acid protein assay (Pierce Biotechnology, IL, United State). After heating at 95 °C for 5 min, protein was separated by 10–12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane. The membranes were blocked with 4% bovine albumin for 1 h and were incubated at 4 °C with specific primary antibodies overnight (Supplemental Table 3). After washing, membranes were incubated with 1:1000 goat anti-rabbit IgG horseradish peroxidase (HRP)-linked antibody (Cat No. 7074 S; Cell Signaling, Danvers, MA, USA) or 1:1000 goat anti-mouse-HRP antibody (Cat No. ab6789, Abcam) and signal were developed by using enhanced chemiluminescent (ECL) horseradish peroxidase substrate (Thermo Fisher Scientific, United State). Levels of protein expression were done in triplicate and intensity was quantified by ImageJ 1.50i software (National Institute of Health, USA). Statistical analysis Results were expressed as means ± SE. One-way analysis of variance with Tukey’s multiple comparisons test was used for multiple sets of independent data. The level of significance for statistical test was P < 0.05. All data were analyzed by GraphPad Prism 10 for macOS (GraphPad Software, San Diego, CA). Results Potassium oxonate injection elevated serum level of uric acid while reducing urinary urate excretion. Supplementation of Pandanus amaryllifolius extract alleviated hyperuricemia Experimental timeline was depicted in Fig. 1A. Rats were intraperitoneally injected with vehicle (denoted as C) or potassium oxonate (PO), a uricase inhibitor, on experimental days 1, 7 and 14. During the 14 days, rats were orally administered with vehicle control (denoted as P0) or Pandanus amaryllifolius extract (PA) in different doses (i.e., 0.5, 1 and 2 mg/kg; denoted as P0.5, P1 and P2, respectively) or allopurinol (Allo, a xanthine oxidase inhibitor) or benzbromarone (Benz, uricouric drug). Regarding Folin-Ciocalteu method, crude PA extract in the present study contained total phenolic and flavonoid content of 64.4 ± 0.06 mg/g crude extract and 12.15 ± 0.19 mg/g, respectively (Table 1). Non-treated P0 rats exhibited significantly high serum level of uric acid from the first day of injection until day 14 and a smaller amount of uric acid was excreted into the urine. Xanthine oxidase (XOD) activity was increased in non-treated P0 rats in the serum and liver, a tissue known to highly express XOD (Fig. 1B), indicating that high serum in P0 rats was due to overproduction of uric acid. Allo had a potent XOD inhibitory effect as shown by marked reduction in serum uric acid from the first dose, while Benz exhibited less potency. PA in all 3 doses did not decrease serum level of uric acid on the 1 st day of supplementation. On day 7, however, P2, the highest dose of 2 mg/kg, significantly reduced serum uric acid to the same level as Benz treatment. After 14 day of supplementation, P0.5, P1 and P2 significantly reduced serum uric acid to the same level as in Benz-treated group, but not as low as that in Allo group (Fig. 1C). Non-treated P0 rats exhibited renal damage as shown by a significant increase in serum creatinine without any change in blood urea nitrogen (BUN). Supplementation of Benz and PA increased urinary uric acid excretion and ameliorated renal damage as indicated by normal serum creatinine. Evidently, urinary creatinine did not change in any groups (Fig. 1C–D). Uricosuric efficacy of PA was dose-dependent (urinary uric acid excretion in P2 was higher than in P1) but still lower than that of Benz. Fig. 1Anti-hyperuricemic and antioxidant properties of Pandanus amaryllifolius Roxb. extract. A) experimental timeline, after acclimatize for 7 days, male rats (n = 5 each) were intraperitoneally injected with vehicle (denoted as C) or potassium oxonate on experimental day 1, 7 and 14. During 14 days, rats were oral administered with vehicle model control (denoted as P0) or Pandanus amaryllifolius extract (PA) in different doses (i.e., 0.5, 1 and 2 mg/kg; denoted as P0.5, P1 and P2, respectively) or allopurinol (Allo) or benzbromarone (Benz). Thereafter, all rats were sacrificed. Blood was collected from tail vein two hours after potassium oxonate injection to determine serum level of uric acid,, B) XOD activity in liver and serum, C) serum uric acid levels on 1 st, 7th and 14th day of treatment, serum creatinine and BUN on 14th day of treatment D) urinary uric acid concentration and urinary creatine level on 1 st, 7th and 14th day of treatment. E) Serum levels of SOD and GPX on 14th day of treatment. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Anti-hyperuricemic and antioxidant properties of Pandanus amaryllifolius Roxb. extract. A) experimental timeline, after acclimatize for 7 days, male rats (n = 5 each) were intraperitoneally injected with vehicle (denoted as C) or potassium oxonate on experimental day 1, 7 and 14. During 14 days, rats were oral administered with vehicle model control (denoted as P0) or Pandanus amaryllifolius extract (PA) in different doses (i.e., 0.5, 1 and 2 mg/kg; denoted as P0.5, P1 and P2, respectively) or allopurinol (Allo) or benzbromarone (Benz). Thereafter, all rats were sacrificed. Blood was collected from tail vein two hours after potassium oxonate injection to determine serum level of uric acid,, B) XOD activity in liver and serum, C) serum uric acid levels on 1 st, 7th and 14th day of treatment, serum creatinine and BUN on 14th day of treatment D) urinary uric acid concentration and urinary creatine level on 1 st, 7th and 14th day of treatment. E) Serum levels of SOD and GPX on 14th day of treatment. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Table 1Total phenolic and flavonoid content in Pandanus amaryllifolius Roxb.ParametersMethod n Mean ± SETotal phenolic content (mg GAE/g crude extract)Folin-Ciocalteu364.4 ± 0.06Total flavonoidColorimetric assay kit312.15 ± 0.19 Table 1Total phenolic and flavonoid content in Pandanus amaryllifolius Roxb.ParametersMethod n Mean ± SETotal phenolic content (mg GAE/g crude extract)Folin-Ciocalteu364.4 ± 0.06Total flavonoidColorimetric assay kit312.15 ± 0.19 Total phenolic and flavonoid content in Pandanus amaryllifolius Roxb. Pandanus amaryllifolius displayed antioxidant activity by up-regulating activity of superoxide dismutase and glutathione peroxidase Un-treated hyperuricemic rats (HUA; P0) exhibited lower SOD and GPX activites than control group (Fig. 1E). While PA supplementation at low dose, P0.5, did not change SOD and GPX levels, P1 group (1 g/kg PA) exhibited higher SOD level but not GPX, meanwhile the highest dose of 2 g/kg PA increased both SOD and GPX levels when compared with un-treated HUA. SOD and GPX levels were fully restored to control in Allo and Benz treated-groups (Fig. 1E). Pandanus amaryllifolius displayed uricosuric property by down-regulating urate reabsorption and up-regulating urinary urate excretion into urine, and alleviated HUA-induced kidney inflammation Lower urinary urate excretion in HUA was due to an increase in urate reabsorption and a reduction in urate excretion. mRNA expression data showed high mRNA expression of URAT1 and GLUT9, and down-regulation of ABCG2 and OAT3 (Fig. 2A). Allo and Benz-treated groups exhibited strong potency as shown by the expression of urate transporters returning towards the control level and even below the level of control for GLUT9, while the expression of ABCG2 and OAT3 was higher than in P0 and control groups. It was clear that PA supplementation enhanced urinary urate excretion through suppression of urate reabsorption (down-regulating URAT1 and GLUT9) and enhancement of urate excretion (up-regulating ABCG2 and OAT3) in a dose dependent manner. As for the low dose of PA, P0.5 was found to up-regulate ABCG2 and OAT3 without affecting the expression of URAT1 or GLUT9. On the other hand, high dose, P2 suppressed urate reabsorption and stimulated urate excretion, but with less potency than Allo and Benz (Fig. 2A). The study of protein expression by Western blot and immunoperoxidase confirmed the results of the mRNA expression. Furthermore, hyperuricemia caused a low-grade inflammation as shown by high protein expression of IL-6, which was restored to control by PA supplementation (P1 and P2) and hypouricemic drugs (Figs. 2B–C). As expected, pathohistology of kidney corresponded with serum markers of kidney function. H&E staining and Masson’s trichome staining (Fig. 3A and B, respectively) showed pathological signs in non-treated P0 rats, i.e., dilation of renal tubule, swelling of tubular cells, enlarged Bowman’s capsule space and an increase in renal weight (Table 2). Pathological changes were reversed to normal histology in P1, P2, and in the Allo and Benz-treated groups (Fig. 3A). On the other hand, with Masson’ trichrome staining, untreated HUA rats showed no serious sign of fibrosis (Fig. 3B), however, they exhibited higher NLRP3 inflammasome activation, and increased in pro-inflammatory cytokine (IL-1β) and premature cell senescence marker (P16) levels. All of these changes were restored to control levels after PA/Benz supplementation (Figs. 3C–F), even though, renal weight of PA supplemented rats remained higher than control (Table 2). Individual data for body weight, organ weights and normalized weights showed in Supplemental Table 4. Fig. 2Pandanus amaryllifolius Roxb. extract suppressed urate reabsorption and stimulated urinary urate excretion. A) mRNA expression of urate reabsorption (e.g., an apical urate/anion exchanger, URAT1; and a basolateral glucose transporter 9, GLUT9 (or SLC2A9)) and urate excretion (e.g., apical ATP-binding cassette subfamily G2, ABCG2; and basolateral urate/dicarboxylate exchangers, OAT1/3) in renal cortex, B) protein expression of URAT1, ABCG2 and IL-6 normalized by β-actin (ACTB) in renal cortex, C) representative images of renal cortex staining antibodies against URAT1, GLUT9 and ABCG2 by immunoperoxidase method. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Pandanus amaryllifolius Roxb. extract suppressed urate reabsorption and stimulated urinary urate excretion. A) mRNA expression of urate reabsorption (e.g., an apical urate/anion exchanger, URAT1; and a basolateral glucose transporter 9, GLUT9 (or SLC2A9)) and urate excretion (e.g., apical ATP-binding cassette subfamily G2, ABCG2; and basolateral urate/dicarboxylate exchangers, OAT1/3) in renal cortex, B) protein expression of URAT1, ABCG2 and IL-6 normalized by β-actin (ACTB) in renal cortex, C) representative images of renal cortex staining antibodies against URAT1, GLUT9 and ABCG2 by immunoperoxidase method. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Fig. 3High uric acid induced renal lesion, inflammation and exhibited premature cellular aging. Supplementation of Pandanus amaryllifolius Roxb. extract ameliorated inflammation and premature cellular aging. A and B) Representative images of renal cortex section stained with H&E and Masson’s trichrome, arrows indicate dilation of renal tubule, swelling of tubular cells, and fibrosis, C–F) protein expression of NLRP3 inflammasome, IL-1β and P16 analyzed by Western blot. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. High uric acid induced renal lesion, inflammation and exhibited premature cellular aging. Supplementation of Pandanus amaryllifolius Roxb. extract ameliorated inflammation and premature cellular aging. A and B) Representative images of renal cortex section stained with H&E and Masson’s trichrome, arrows indicate dilation of renal tubule, swelling of tubular cells, and fibrosis, C–F) protein expression of NLRP3 inflammasome, IL-1β and P16 analyzed by Western blot. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Table 2Body weight and serval organ weights. Rats were intraperitoneal injected with potassium oxonate to induce hyperuricemia (HUA). HUA rats were oral administered for 14 days with 0.3% tween 20 vehicle control (P0) or 0.5, 1 and 2 g/kg pandanus extract (P0.5, P1 and P2), allopurinol (Allo) and benzbromarone (Benz). Data are represented as mean ± SE. The multiple comparisons are analyzed by one-way ANOVA with Tukey’s post-hoc analysis. Superscripts that not sharing the common superscript are significant different.weight n ControlP0P0.5P1P2AlloBenzInitial body weight (g)5259.2 ± 12.1267.0 ± 10.7272.2 ± 10.9257.1 ± 7.2269.4 ± 8.3272.2 ± 9.8268.5 ± 6.8Final body weight (g)5392.2 ± 13.7387.7 ± 11.6397.4 ± 8.8383.6 ± 10.9400.3 ± 6.1396.6 ± 8.5390.3 ± 7.6Absolute organ weight (g)Heart51.01 ± 0.031.22 ± 0.081.05 ± 0.031.09 ± 0.031.08 ± 0.041.01 ± 0.041.02 ± 0.04Kidney51.92 ± 0.04a2.18 ± 0.05bc2.18 ± 0.04bc2.29 ± 0.04b2.26 ± 0.06b1.96 ± 0.04ac2.11 ± 0.10abLiver510.22 ± 0.4110.02 ± 0.8610.03 ± 0.579.82 ± 0.279.69 ± 0.298.99 ± 0.679.01 ± 0.43Normalized organ weight (g/kg)Heart52.60 ± 0.15ab3.14 ± 0.17a2.64 ± 0.07ab2.86 ± 0.09ab2.72 ± 0.13ab2.55 ± 0.12b2.62 ± 0.13abKidney54.91 ± 0.20a5.65 ± 0.06bc5.51 ± 0.20ab5.99 ± 0.15b5.67 ± 0.18bc4.95 ± 0.10ac5.41 ± 0.19abLiver526.2 ± 1.526.0 ± 2.525.2 ± 1.325.6 ± 0.524.2 ± 0.822.6 ± 1.523.1 ± 0.9 Table 2Body weight and serval organ weights. Rats were intraperitoneal injected with potassium oxonate to induce hyperuricemia (HUA). HUA rats were oral administered for 14 days with 0.3% tween 20 vehicle control (P0) or 0.5, 1 and 2 g/kg pandanus extract (P0.5, P1 and P2), allopurinol (Allo) and benzbromarone (Benz). Data are represented as mean ± SE. The multiple comparisons are analyzed by one-way ANOVA with Tukey’s post-hoc analysis. Superscripts that not sharing the common superscript are significant different.weight n ControlP0P0.5P1P2AlloBenzInitial body weight (g)5259.2 ± 12.1267.0 ± 10.7272.2 ± 10.9257.1 ± 7.2269.4 ± 8.3272.2 ± 9.8268.5 ± 6.8Final body weight (g)5392.2 ± 13.7387.7 ± 11.6397.4 ± 8.8383.6 ± 10.9400.3 ± 6.1396.6 ± 8.5390.3 ± 7.6Absolute organ weight (g)Heart51.01 ± 0.031.22 ± 0.081.05 ± 0.031.09 ± 0.031.08 ± 0.041.01 ± 0.041.02 ± 0.04Kidney51.92 ± 0.04a2.18 ± 0.05bc2.18 ± 0.04bc2.29 ± 0.04b2.26 ± 0.06b1.96 ± 0.04ac2.11 ± 0.10abLiver510.22 ± 0.4110.02 ± 0.8610.03 ± 0.579.82 ± 0.279.69 ± 0.298.99 ± 0.679.01 ± 0.43Normalized organ weight (g/kg)Heart52.60 ± 0.15ab3.14 ± 0.17a2.64 ± 0.07ab2.86 ± 0.09ab2.72 ± 0.13ab2.55 ± 0.12b2.62 ± 0.13abKidney54.91 ± 0.20a5.65 ± 0.06bc5.51 ± 0.20ab5.99 ± 0.15b5.67 ± 0.18bc4.95 ± 0.10ac5.41 ± 0.19abLiver526.2 ± 1.526.0 ± 2.525.2 ± 1.325.6 ± 0.524.2 ± 0.822.6 ± 1.523.1 ± 0.9 Body weight and serval organ weights. Rats were intraperitoneal injected with potassium oxonate to induce hyperuricemia (HUA). HUA rats were oral administered for 14 days with 0.3% tween 20 vehicle control (P0) or 0.5, 1 and 2 g/kg pandanus extract (P0.5, P1 and P2), allopurinol (Allo) and benzbromarone (Benz). Data are represented as mean ± SE. The multiple comparisons are analyzed by one-way ANOVA with Tukey’s post-hoc analysis. Superscripts that not sharing the common superscript are significant different. Besides being excreted into the urine, urate was also excreted into the intestine, especially in the ileum segment. HUA rats exhibited lower mRNA (Fig. 4A) and protein expression of ABCG2 (Figs. 4B–C). P1 and P2 significantly upregulated ABCG2 protein expression beyond that in the normal control rats. The expression was also greater in Benz group. Fig. 4Supplementation of Pandanus amaryllifolius Roxb. extract stimulated urate excretion in the ileum. (A) mRNA expression of ABCG2 (apical ATP-binding cassette subfamily G2), (B) representative images of ileum section stained with antibody against ABCG2, (C) protein expression of ABCG2 analyzed by Western blot. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Supplementation of Pandanus amaryllifolius Roxb. extract stimulated urate excretion in the ileum. (A) mRNA expression of ABCG2 (apical ATP-binding cassette subfamily G2), (B) representative images of ileum section stained with antibody against ABCG2, (C) protein expression of ABCG2 analyzed by Western blot. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Hyperuricemia caused hepatic fat accumulation and hepatic inflammation. Supplementation of Pandanus amaryllifolius and hypouricemic drugs, allopurinol and benzbromarone, reversed these liver abnormalities Figure 5A depicts representative micrographs of liver sections stained with H&E. HUA rats (P0) exhibited lipid droplets and high amount of triglyceride (Figs. 5A–B) despite no change in liver weight (Table 2). As expected, mRNA expression of fatty acid synthesis markers, fatty acid synthase and SREBP-1c, were upregulated, while the markers of lipolysis, PPARα and PGC-1α were down-regulated in the liver in HUA rats (Figs. 5E–F). Liver of HUA rats also showed high level of MDA (end product of lipid peroxidation, a marker of oxidative stress) as well as high protein expression of proinflammatory cytokines, IL-1β and IL-6 (Fig. 5C–D). Even at a low dose (0.5 g/kg), PA significantly decreased hepatic triglyceride, MDA and increased PGC-1α expression in the liver when compared with non-treated HUA P0. However, P0.5 showed only a tendency to decrease IL-1β and IL-6, and had no effect on fatty acid synthesis markers. PA supplementation at higher doses, i.e., P1 and P2, further decreased hepatic triglyceride, MDA, proinflammatory cytokines, fatty acid synthesis markers and increased lipolysis markers nearly to the same levels as in Allo and Benz-treated groups (Figs. 5B–F). Therefore, PA exhibited hepatoprotective effects against hyperuricemia in a dose-dependent manner. Fig. 5Supplementation with the Pandanus amaryllifolius Roxb. extract alleviated high uric acid-induced hepatic lipid accumulation. This was achieved by suppressing lipogenesis while stimulating lipolysis, with effects being dose-dependent. A) Representative images of liver section stained with H&E, B) liver triglyceride content, C) malondialdehyde level (marker of oxidative stress), D) mRNA expression of pro-inflammatory cytokines IL-1β and IL-6, E) mRNA expression of lipogenesis markers (fatty acid synthase and SREBP-1c), F) mRNA expression of lipolysis markers (PPARα and PGC-1α). Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Supplementation with the Pandanus amaryllifolius Roxb. extract alleviated high uric acid-induced hepatic lipid accumulation. This was achieved by suppressing lipogenesis while stimulating lipolysis, with effects being dose-dependent. A) Representative images of liver section stained with H&E, B) liver triglyceride content, C) malondialdehyde level (marker of oxidative stress), D) mRNA expression of pro-inflammatory cytokines IL-1β and IL-6, E) mRNA expression of lipogenesis markers (fatty acid synthase and SREBP-1c), F) mRNA expression of lipolysis markers (PPARα and PGC-1α). Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. AMPK and Sirt1 were well-known regulators of lipid metabolism in the liver. P0 displayed significantly lower protein levels of p-AMPK and Sirt1 and had a tendency to decrease total AMPK and p-AMPK/AMPK ratio (Fig. 6A). These findings were associated with hepatic fat accumulation. In agreement with the mRNA expression data, non-treated P0 rats exhibited hepatic inflammation and significantly higher protein expression of NLRP3, IL-1β and IL-6 (Fig. 6B). Similar to the effect of Benz, 1 and 2 g/kg PA supplementation restored p-AMPK and Sirt1 and the level of cytokines to those control (Fig. 6). As for the serum lipid profile, un-treated HUA rats exhibited lower levels of total cholesterol, HDL level and non-HDL. Both doses P1 and P2 restored total cholesterol and non-HDL to control, while lowering serum triglyceride level (Table 3). Fig. 6Pandanus amaryllifolius Roxb. extract supplementation alleviated hepatic inflammation and lipid metabolism. Protein expression of (A) AMPK and Sirt1 signaling pathway (master regulator of lipid metabolism in liver) and (B) NLRP3, proinflammatory cytokines 1β and IL-6 in liver. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Pandanus amaryllifolius Roxb. extract supplementation alleviated hepatic inflammation and lipid metabolism. Protein expression of (A) AMPK and Sirt1 signaling pathway (master regulator of lipid metabolism in liver) and (B) NLRP3, proinflammatory cytokines 1β and IL-6 in liver. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Table 3Serum lipid profile. Results were expressed as means ± SE. The differences between five experimental groups were determined by one-way ANOVA followed by Tukey post hoc test. Results shared the same superscript were not significant different. Results that do not show the same superscript were statistical different at P < 0.05.Lipid profile (mg/dL) n CP0P0.5P1P2BenzTriglyceride551.40 ± 6.25a38.20 ± 4.25ab47.20 ± 3.57a25.20 ± 4.33bc17.60 ± 2.94c20.80 ± 3.37bcTotal cholesterol572.60 ± 1.12a62.80 ± 0.97b65.20 ± 0.97bc70.00 ± 1.05ac70.20 ± 1.36ac64.80 ± 1.77bcHDL530.20 ± 0.66a27.60 ± 0.68b28.20 ± 0.66ab29.60 ± 0.40ab29.80 ± 0.74ab27.60 ± 0.24bLDL54.80 ± 0.37a3.80 ± 0.37a3.63 ± 0.18a4.40 ± 0.24a4.40 ± 0.24a4.20 ± 0.37aNon-HDL542.40 ± 0.93a35.20 ± 1.02b37.00 ± 0.98bc40.40 ± 0.98ac40.40 ± 0.93ac37.20 ± 1.53bcTC/HDL-c52.42 ± 0.04a2.28 ± 0.07a2.34 ± 0.04a2.34 ± 0.04a2.38 ± 0.04a2.34 ± 0.04a Table 3Serum lipid profile. Results were expressed as means ± SE. The differences between five experimental groups were determined by one-way ANOVA followed by Tukey post hoc test. Results shared the same superscript were not significant different. Results that do not show the same superscript were statistical different at P < 0.05.Lipid profile (mg/dL) n CP0P0.5P1P2BenzTriglyceride551.40 ± 6.25a38.20 ± 4.25ab47.20 ± 3.57a25.20 ± 4.33bc17.60 ± 2.94c20.80 ± 3.37bcTotal cholesterol572.60 ± 1.12a62.80 ± 0.97b65.20 ± 0.97bc70.00 ± 1.05ac70.20 ± 1.36ac64.80 ± 1.77bcHDL530.20 ± 0.66a27.60 ± 0.68b28.20 ± 0.66ab29.60 ± 0.40ab29.80 ± 0.74ab27.60 ± 0.24bLDL54.80 ± 0.37a3.80 ± 0.37a3.63 ± 0.18a4.40 ± 0.24a4.40 ± 0.24a4.20 ± 0.37aNon-HDL542.40 ± 0.93a35.20 ± 1.02b37.00 ± 0.98bc40.40 ± 0.98ac40.40 ± 0.93ac37.20 ± 1.53bcTC/HDL-c52.42 ± 0.04a2.28 ± 0.07a2.34 ± 0.04a2.34 ± 0.04a2.38 ± 0.04a2.34 ± 0.04a Serum lipid profile. Results were expressed as means ± SE. The differences between five experimental groups were determined by one-way ANOVA followed by Tukey post hoc test. Results shared the same superscript were not significant different. Results that do not show the same superscript were statistical different at P < 0.05. Hyperuricemic rats exhibited pancreatic inflammation and developed β-cell dysfunction which resulted in aberrant glucose metabolism Non-treated P0 rats exhibited higher serum fasting glucose and HbA1C (Fig. 7A and B). together with pancreatic dysfunction as shown by higher cell apoptotic markers and lower protein expression of insulin that corresponded to smaller islet of Langerhans (Fig. 7D and E). Down-regulation of insulin signaling molecules, i.e., p-Akt, p-Akt/Akt and p-IRS1 in P0 was also evident (Fig. 7F). PA supplementation at 1 and 2 g/kg fully restored serum fasting glucose, HbA1C and insulin to control level. Meanwhile treatment with Benz failed to correct the hyperglycemic condition even through the serum level of insulin was further elevated when compared to PA-treated groups (Fig. 7A–C). Pancreatic cell apoptotic markers and expression of insulin protein and its signaling molecules in Pandanus and Benz-treated rats were restored to the same levels of control (Fig. 7D–F). Fig. 7Pandanus amaryllifolius Roxb. extract supplementation alleviated high uric acid-induced insulin resistance and pancreatic β cell dysfunction. A) fasting glucose, B) level of HbA1C, C) serum level of insulin, D) protein expression of PARP and cleaved caspase 3 (apoptotic markers) and insulin in pancreas, E) representative images of pancreas section with H&E staining, F) protein expression of insulin signaling molecules, i.e., p-IRS1, IRS1, p-Akt and Akt. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Pandanus amaryllifolius Roxb. extract supplementation alleviated high uric acid-induced insulin resistance and pancreatic β cell dysfunction. A) fasting glucose, B) level of HbA1C, C) serum level of insulin, D) protein expression of PARP and cleaved caspase 3 (apoptotic markers) and insulin in pancreas, E) representative images of pancreas section with H&E staining, F) protein expression of insulin signaling molecules, i.e., p-IRS1, IRS1, p-Akt and Akt. Results are expressed as means ± SE with individual values. The differences between experimental groups were determined by one-way ANOVA followed by Tukey post-hoc test. The results not sharing a common superscript letter were significantly different at P < 0.05. Discussion Either an overproduction of uric acid by the liver or inadequate excretion by the kidney or their combination could cause hyperuricemia (HUA) which was a risk factor for developing gout, cardiovascular disease, hypertension, type 2 diabetes mellitus and chronic kidney disease1,3–5. The hyperuricemia-induced oxidative stress in chronic kidney disease can result in increased renal tubular epithelial cell apoptosis and eventually impaired renal function29. Gout could be effectively managed and potentially cured by decreasing the overall urate burden with serum urate-lowering therapy such as inhibiting xanthine oxidase or inhibiting urate reabsorption or stimulating urate excretion into the renal tubules. Potassium oxonate (PO) can cause uric acid build up in serum by inhibiting uricase enzyme that normally converts uric acid into allantoin, thus causing uric acid to build up in serum. In consistence with the previous investigation27, the present study demonstrated that potassium oxonate-treated rodents had significantly higher serum and hepatic XOD activity (a key enzyme responsible for the synthesis of UA) and elevated serum uric acid (Fig. 1), indicating a successful HUA model. One potential concern is that residual PO, a competitive uricase inhibitor, might interfere with the uricase-based assay used to measure uric acid, particularly in samples collected two hours post-injection. However, our methodology aligns with the established and standard practice used in numerous published preclinical hyperuricemia models, where the uricase-based assay is successfully employed to demonstrate the expected increase in uric acid following PO treatment8,30. There are 2 main reasons that effectively minimize interference. i) high dilution factor; the assay protocol recommends a significant dilution of the biological sample into the reaction mix. This substantially reduces the concentration of residual PO, mitigating its inhibitory effect and ii) use of exogenous high-activity uricase; the commercial kit provides a high concentration of highly active, purified uricase. This exogenous enzyme load is sufficient to overcome the inhibitory effect of any residual, low concentration of PO in the diluted sample, ensuring that the measured values accurately reflect the true uric acid levels. The elimination of uric acid was mediated by a complexed balance between urate reabsorption via an apical urate/anion exchanger URAT1 and basolateral GLUT9 (or SLC2A9), and urate excretion via apical ATP-binding cassette subfamily G2 (ABCG2) and basolateral urate/dicarboxylate exchangers (OAT1/3)2,16. A uricosuric drugs, benzbromarone that inhibits SLC2A9, URAT1 and OAT42, was used widely despite being toxic to the liver and causing diarrhea31. Therefore, alternative therapies for the treatment of HUA was needed. In agreement with previous finding32,33, the present HUA rat model exhibited a decrease in uric acid excretion by the kidney and the intestine. Also, consistent with other findings8,12, HUA rats exhibited renal histopathological lesions, renal interstitial mild edema, tubular dilatation, mild interstitial fibrosis and impaired kidney function as indicated by elevated serum CRE and BUN (Figs. 1 and 3). In accordance with previous reports of the XOD inhibitory and anti-inflammatory effects of PA20–22, fourteen day PA treatment in this study resulted in a marked dose dependent decrease in hepatic and serum XOD levels with the effectiveness of anti-hyperuricemic activity comparable to those of Allo and Benz, the widely used drugs for treatment of hyperuricemia. Supplementation with PA increased renal and extra-renal uric acid excretion and improved kidney function in a dose dependent fashion with uric acid excretion in the group given 2 g/kg of PA being lower than that of the Benz-treated group (Figs. 1 and 2, and 4). PA exhibits a dual therapeutic effect, engaging both xanthine oxidase inhibition (confirmed by reduced serum and liver XOD activity) and a uricosuric-like action (confirmed by enhanced urinary uric acid excretion and modulation of renal transporters). Based on the integrated data, we cannot definitively assign one mechanism as the “primary contributor,” as both mechanisms appear to significantly contribute to the observed anti-hyperuricemic outcome. In addition, PA inhibited NLRP3 inflammasome activation, thereby alleviating tubular inflammation and renal interstitial fibrosis (Fig. 3). The present study found that Allo exerted an XOD inhibitory effect and inhibited urate reabsorption in HUA model, however other study showed no change in urate reabsorption34. The mRNA and protein analyses revealed that Allo was able to suppress mRNA and protein expression of urate transporters, thus compromising urate reabsorption while enhancing the expression of urate excretion genes and proteins, and alleviating renal inflammation (Figs. 2, 3 and 4), which was inconsistent with a report by Sung and co-workers35. We propose that the differences in findings, despite similar dosage and animal models, are attributable to the duration of treatment. The shorter 5-day duration utilized in previous studies35 may have been sufficient for pharmacological inhibition of XOD, but may not prolong enough to induce the necessary transcriptional and translational adaptations (i.e., changes in mRNA/protein expression) of renal uric acid transporters (i.e., URAT1, GLUT9, OAT1). Furthermore, a short duration may not have been sufficient to alleviate the underlying potassium oxonate-induced renal inflammation, which itself can confound transporter expression and activity, masking the effects of allopurinol. In agreement with other finding36, Allo was found to suppress NLRP3 inflammasome activation and alleviate renal inflammation and histopathology. Besides the uricosuric activity, Benz also exhibited XOD inhibitory in serum and liver in this study, but not in other study30. The observed inhibition of Xanthine Oxidase (XOD) activity by benzbromarone is likely attributable to an indirect regulatory mechanism rather than direct antagonism. The enzyme that catalyzes the final steps of purine breakdown is known as Xanthine Oxidoreductase (XOR), which exists in two main interconvertible forms: Xanthine Dehydrogenase (XDH) (the physiologically dominant form) and the superoxide-producing Xanthine Oxidase (XO). Crucially, hyperuricemia-driven oxidative stress favors the conversion of XDH into the damaging XO form. When benzbromarone lowers serum uric acid, its potent uricosuric action dramatically reduces the systemic oxidative and inflammatory burden. This reduction may effectively help to shift the enzyme equilibrium back toward the benign XDH form. This resulting modulation of the enzymatic redox state accounts for the observed and measurable decrease in total XOD activity in hepatic and serum assays, providing the basis for the proposed indirect mechanism of XOD inhibition by benzbromarone. The present study showed that hepatic lipid accumulation in HUA was partly mediated by NLRP3 activation (Figs. 5 and 6). Pandanus sp. was previously reported to have anti-hyperlipidemic activity and reduce accumulation of triglyceride/cholesterol in a liver of diabetic hamsters37. Other finding showed that allopurinol inhibited NLRP3 activation, down-regulated PPARα and FAS, thereby reducing liver inflammation and lipid accumulation in diabetic rats38. The present study found that PA was able to suppress NLRP3 inflammasome which leads to amelioration of inflammation and fatty liver. Supplementation of PA enhanced lipolysis and suppressed lipid synthesis by increasing the expression of PPARα that promoted lipid hydrolysis and oxidation and upregulating AMPK that suppressed lipogenesis (Figs. 5 and 6and Table 3). Besides fatty liver, high uric acid has been found to be associated with abnormal glucose metabolism and insulin resistance (IR) in several peripheral tissues in human and rodents39–41, for examples, liver, skeletal muscles, adipocyte, pancreatic β cells and cardiac myocytes. HUA mice exhibited impaired glucose tolerance and insulin tolerance41 indicating abnormal glucose metabolism. High uric acid induced oxidative stress and led to dysfunction of pancreatic β-cell (impaired insulin expression and secretion) and human hepatoma (HepG2) cell line by suppressing IRS1/2 and Akt signaling pathway. Pretreatment with antioxidant rescued HUA-induced insulin resistance40,41. Consistent with previous findings41, this study found that HUA rats exhibited elevated fasting glucose, high HbA1C level and reduced insulin expression in the pancreas, indicating β-cell dysfunction (Fig. 7). Interestingly, besides having an anti-inflammatory, PA exhibited an antihyperglycemic effect in human and rodents24,37. Reshidan and co-workers (2019) showed that PA supplementation decreased body weight gain, serum triglyceride level, fasting glucose level and the size of adipocyte in a fructose-induced metabolic syndrome rat model24. Supplementation of PA improved insulin signaling and increased insulin expression and secretion by pancreatic β cells (Fig. 7). This effect may be attributed to the antioxidant and anti-inflammatory properties inherent to PA, which has been shown to be a rich source of phenolic and flavonoid compounds that were known to have antioxidant and anti-inflammatory properties. The ethanol extract of PA exhibited high levels of flavonoids and polyphenols. Specifically, the extract is characterized by the presence of catechin (0.613 mg/g), kaempferol (0.278 mg/g), and the phenolic acid gallic acid (0.423 mg/g), which likely contribute to the observed antioxidant and anti-inflammatory properties25. PA was recently reported to have a high antioxidant activity, with IC50 values of 12 µg/mL and 26 µg/mL for DPPH and ABTS assays, respectively42. Oxidative stress and chronic inflammation collectively induce insulin resistance through a detrimental feedback loop that compromises both cellular insulin signaling and pancreatic β-cell function43–46. Antioxidant and anti-inflammatory strategies mitigate insulin resistance by breaking the cycle of oxidative damage and inflammation. Antioxidants scavenge ROS, preventing the activation of stress pathways that inhibit IRS-1. This preserves the PI3K/AKT axis, enabling normal GLUT4 trafficking and enhancing glucose disposal in target cells. Concurrently, anti-inflammatory agents suppress proinflammatory cytokines, eliminating their inhibitory effect on insulin signaling. By reducing both the oxidative and inflammatory burden, these interventions protect β-cell viability and function while restoring cellular insulin sensitivity45,46. The lack of phytochemical characterization poses a limitation to the translational potential. Specifically, while total phenolic and flavonoid content were provided, the study did not identify or quantify the specific bioactive compounds responsible for the observed uricosuric, antioxidant, and anti-inflammatory effects of the Pandanus amaryllifolius extract meaning the exact molecules responsible for modulating urate transporters (URAT1 or ABCG2) or suppressing inflammation (IL-6 or NLRP3) remain unknown. Without knowing the specific active ingredients, quality and potency of PA extracts may vary, and may need further standardization and development into a pharmaceutical or nutraceutical product. Therefore, future research direction should focus on identifying the active compounds, validating their specific mechanisms, and assessing long-term safety to move PA toward clinical application. In summary, this present study showed that Pandanus amaryllifolius Roxb. extract exerted a dose-dependent anti-hyperuricemic effect by regulating both the production and elimination of uric acid. Furthermore, it has been shown to be safe for use in animals. Additionally, Pandanus amaryllifolius Roxb. extract also ameliorated hyperuricemic-associated insulin resistance, oxidative stress, lipid accumulation and tissue inflammation. These findings suggested that Pandanus amaryllifolius Roxb. had a strong potential to be further developed for use in the prevention of hyperuricemia and its associated complications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4